المؤلفون: H. C. Chung, Y-J. Bang, J. M. Xu, F. Lordick, A. Sawaki, O. Lipatov, M. Lehle, М. Pickl, J. Ruschoff, E. Van Cutsem

المصدر: Креативная хирургия и онкология, Vol 0, Iss 4, Pp 16-22 (2017)

مصطلحات موضوعية: рак желудка, химиотерапия, тест her2, трастузумаб, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.surgonco.ru/jour/article/view/185; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093

URL الوصول: https://doaj.org/article/d5aeddf98eff412786d5d21ee507bca1

المؤلفون: A. V. Sultanbaev, A. F. Nasretdinov, M. G. Galeev, K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, R. T. Ayupov, R. R. Rakhimov, O. N. Lipatov, A. A. Izmaylov, I. A. Menshikova, G. A. Serebrennikov, D. O. Lipatov

المصدر: Опухоли женской репродуктивной системы, Vol 19, Iss 2, Pp 16-24 (2023)

مصطلحات موضوعية: brca1/2, germline mutations, screening, breast cancer, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://ojrs.abvpress.ru/ojrs/article/view/1098; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627

URL الوصول: https://doaj.org/article/18f7483b90d34537b8ae9d15b4c2cb8b

المؤلفون: A. V. Sultanbaev, I. V. Kolyadina, Sh. I. Musin, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, I. A. Menshikova, V. E. Askarov, R. R. Rakhimov, D. O. Lipatov, O. N. Lipatov, M. V. Sultanbaev, V. M. Zabelin, A. A. Izmailov, R. T. Ayupov, А. В. Султанбаев, И. В. Колядина, Ш. И. Мусин, А. Ф. Насретдинов, Н. И. Султанбаева, К. В. Меньшиков, И. А. Меньшикова, В. Е. Аскаров, Р. Р. Рахимов, Д. О. Липатов, О. Н. Липатов, М. В. Султанбаев, В. М. Забелин, A. А. Измайлов, Р. Т. Аюпов, А. А. Измайлов

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 130-138 ; Медицинский Совет; № 22 (2023); 130-138 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: эндокринная терапия, metastatic breast cancer, progression free survival, clinical practice, endocrine therapy, метастатический рак молочной железы, выживаемость без прогрессии, клиническая практика

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7982/7069; Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2021 г. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022. 239 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.; Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014:469251. https://doi.org/10.1155/2014/469251.; Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541–552. https://doi.org/10.1038/nrclinonc.2015.99.; Flaum LE, Gradishar WJ. Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. In: Gradishar W (ed.). Optimizing Breast Cancer Management. Cancer Treatment and Research. Vol. 173. Springer, Cham; 2018, pp. 141–154. https://doi.org/10.1007/978-3-319-70197-4_9.; Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H et al. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst. 2004;96(3):210–218. https://doi.org/10.1093/jnci/djh022.; Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O’Hara M, Perini R et al. Palbociclib (PD0332991) – a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. JAMA Oncol. 2016;2(2):253–260. https://doi.org/10.1001/jamaoncol.2015.4701.; Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129–138. https://doi.org/10.1016/j.ctrv.2016.03.002.; Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer. Drug Des Devel Ther. 2018;12:321–330. https://doi.org/10.2147/DDDT.S137783.; Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303.; Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709.; Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638–3646. https://doi.org/10.1200/JCO.2017.75.6155.; Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. https://doi.org/10.1016/S1470-2045(18)30292-4.; Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875–2884. https://doi.org/10.1200/JCO.2017.73.7585.; Гольдина ТА, Колбин АС, Белоусов ДЮ, Боровская ВГ. Обзор исследований реальной клинической практики. Качественная клиническая практика. 2021;(1):56–63. https://doi.org/10.37489/2588-0519-2021-1-56-63.; Колядина ИВ. Рибоциклиб в лечении больных HR+ HER2-отрицательным распространенным раком молочной железы: обновленные результаты рандомизированных клинических исследований и их роль для клинической практики. Опухоли женской репродуктивной системы. 2021;17(2):58–67. https://doi.org/10.17650/1994-4098-2021-17-2-58-67.; Ганьшина ИП, Филоненко ДА, Гордеева ОО, Лубенникова ЕВ, Колядина ИВ, Мещеряков АА. Рибоциклиб в лечении гормонопозитивного HER2-негативного рака молочной железы. Медицинский совет. 2019;(10):72–80. https://doi.org/10.21518/2079-701X-2019-10-72-80.; Колядина ИВ. По следам SABCS 2022: TOP-12 исследований по распространенному раку молочной железы, которые могут изменить нашу клиническую практику. Современная онкология. 2023;25(1):46–54. https://doi.org/10.26442/18151434.2023.1.202102.; Da Silva SHK, de Oliveira LC, E Silva Lopes MSDM, Wiegert EVM, Motta RST, Ferreira Peres WA. The patient generated-subjective global assessment (PG-SGA) and ECOG performance status are associated with mortality in patients hospitalized with breast cancer. Clin Nutr ESPEN. 2023;53:87–92. https://doi.org/10.1016/j.clnesp.2022.11.019.; Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz- Borrego M et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–1799. https://doi.org/10.1001/jamaoncol.2021.4301.; Колядина ИВ, Поддубная ИВ. ESR1-мутация как потенциальный предсказательный маркер для выбора тактики лечения при гормонорезистентном HR+/HER2-негативном раке молочной железы. Медицинский алфавит. 2020;(29):68–73. https://doi.org/10.33667/2078-5631-2020-29-61-73.; Sanò MV, Martorana F, Lavenia G, Rossello R, Prestifilippo A, Sava S et al. Ribociclib efficacy in special populations and analysis of patient-reported out-comes in the MONALEESA trials. Expert Rev Anticancer Ther. 2022;22(4):343–351. https://doi.org/10.1080/14737140.2022.2052277.; Zhu K, Wu Y, He P, Fan Y, Zhong X, Zheng H, Luo T. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. Cells. 2022;11(16):2508. https://doi.org/10.3390/cells11162508.; China Anti-cancer Association Tumor Drug Clinical Research Committee; Breast Cancer Expert Committee, National Tumor Quality Control Center; Tumor Pathology Committee of China Anti-cancer Association; Boao Institute of Oncology Innovation. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2022;44(7):673–692. (In Chinese) https://doi.org/10.3760/cma.j.cn112152-20220412-00251.; Reinhardt K, Stückrath K, Hartung C, Kaufhold S, Uleer C, Hanf V et al. PIK3CA-mutations in breast cancer. Breast Cancer Res Treat. 2022;196(3):483–493. https://doi.org/10.1007/s10549-022-06637-w.; Kim JH, Lee ST. Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells. Int J Mol Sci. 2022;23(14):7521. https://doi.org/10.3390/ijms23147521.; Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, Arun B. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat. 2022;196(1):143–152. https://doi.org/10.1007/s10549-022-06688-z.; Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714–3728. https://doi.org/10.1002/cncr.32345.; Zhu W, Xu B. Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials. Front Med. 2021;15(2):208–220. https://doi.org/10.1007/s11684-020-0795-4.; Radhi S. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance. Prog Mol Biol Transl Sci. 2016;144:539–562. https://doi.org/10.1016/bs.pmbts.2016.09.009.; https://www.med-sovet.pro/jour/article/view/7982

الاتاحة: https://www.med-sovet.pro/jour/article/view/7982
https://doi.org/10.21518/ms2023-433

المؤلفون: Alexander V. Sultanbaev, Irina V. Kolyadina, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva, Radmir R. Rakhimov, Danila O. Lipatov, Irina A. Menshikova, Adel A. Izmailov, Elena E. Lipatova

المصدر: Современная онкология, Vol 26, Iss 1, Pp 65-72 (2024)

مصطلحات موضوعية: combination endocrine therapy, metastatic breast cancer, pik3ca mutation, luminal her2-negative subtype, cdk4/6 inhibitors, alpelisib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://modernonco.orscience.ru/1815-1434/article/viewFile/630446/145921; https://doaj.org/toc/1815-1434; https://doaj.org/toc/1815-1442; https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8

الاتاحة: https://doi.org/10.26442/18151434.2024.1.202612
https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8

المؤلفون: Alexander V. Sultanbaev, Shamil I. Musin, Konstantin V. Menshikov, Nadezda I. Sultanbaeva, Irina A. Tuzankina, Danila O. Lipatov, Irina A. Menshikova, Mikhail V. Sultanbaev, Dmitry A. Kudlay, Andrey P. Prodeus

المصدر: Современная онкология, Vol 26, Iss 2, Pp 132-138 (2024)

مصطلحات موضوعية: carcinogenesis, v(d)j recombination, antitumor immunity, krec, trec, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://modernonco.orscience.ru/1815-1434/article/viewFile/629825/pdf; https://doaj.org/toc/1815-1434; https://doaj.org/toc/1815-1442; https://doaj.org/article/5ed0020daa5b4dd1849ab3aab2568c61

الاتاحة: https://doi.org/10.26442/18151434.2024.2.202679
https://doaj.org/article/5ed0020daa5b4dd1849ab3aab2568c61

المؤلفون: A. L. Urakov, N. A. Urakova, Z. V. Shubina, L. V. Lovtsova, A. V. Samorodov, K. G. Gurevich, A. P. Stolyarenko, V. I. Korunas, D. O. Lipatov, D. D. Muminov

المصدر: Разработка и регистрация лекарственных средств, Vol 12, Iss 2, Pp 164-173 (2023)

مصطلحات موضوعية: solution for injection, osmotic activity, local irritant effect, post-injection abscess, nicolau's syndrome, Pharmaceutical industry, HD9665-9675

وصف الملف: electronic resource

Relation: https://www.pharmjournal.ru/jour/article/view/1496; https://doaj.org/toc/2305-2066; https://doaj.org/toc/2658-5049

URL الوصول: https://doaj.org/article/f8ad2c2ce3a34ee384e7794dd27d2ed2

المؤلفون: K. V. Menshikov, A. V. Sultanbaev, S. I. Musin, A. A. Izmailov, I. A. Menshikova, V. S. Chalov, N. I. Sultanbaeva, D. O. Lipatov, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, А. А. Измайлов, И. А. Меньшикова, В. С. Чалов, Н. И. Султанбаева, Д. О. Липатов

المصدر: Malignant tumours; Том 13, № 4 (2023); 84-92 ; Злокачественные опухоли; Том 13, № 4 (2023); 84-92 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: рак молочной железы, myofibrosarcoma, radiogenic neoplasms, breast cancer, миофибросаркома, радиоиндуцированные новообразования

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1142/798; https://www.malignanttumors.org/jour/article/view/1142/910; Lord, C. J.; Ashworth, A. The DNA damage response and cancer therapy. Nature 2012, 481, 287–294.; Valerie, K.; Povirk, L. F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003, 22, 5792–5812.; Jaco, I.; Muñoz, P.; Goytisolo, F.; Wesoly, J.; Bailey, S.; Taccioli, G.; Blasco, M. A. Role of mammalian Rad54 in telomere length maintenance. Mol. Cell Biol. 2003, 23, 5572–5580.; Salzano, A.; Kochiashvili, N.; Nergadze, S. G.; Khoriauli, L.; Smirnova, A.; Ruiz-Herrera, A.; Mondello, C.; Giulotto, E. Enhanced gene amplification in human cells knocked down for DNA-Kcs. DNA Repair 2009, 8, 19–28.; Khouriauli, L.; Giulotto, E. Gene amplification in human cells knocked down for RAD54. Genome Integr. 2011, 2, doi:10.1186/2041-9414-2-5.; Keeney, S.; Giroux, C. N.; Kleckner, N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell 1997, 88, 375–384.; Roeder, G. S. Meiotic chromosomes : It takes two to tango. Genes Dev. 1997, 11, 2600–2621.; Moens, P. B.; Kolas, N. K.; Tarsounas, M.; Marcon, E.; Cohen, P. E.; Spyropoulos, B. The time course and chromosomal localization of recombination-related proteins at meiosis in the mouse are compatible with models that can resolve the early DNA-DNA interactions without reciprocal recombination. J. Cell Sci. 2002, 115, 1611–1622.; Baker, S. M.; Plug, A. W.; Prolla, T. A.; Bronner, C. E.; Harris, A. C.; Yao, X.; Christie, D. M.; Monell, C.; Arnheim, N.; Bradley, A.; et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet. 1996, 13, 336–342.; Turner, J. M.; Aprelikova, O.; Xu, X.; Wang, R.; Kim, S.; Chandramouli, G. V.; Barrett, J. C.; Burgoyne, P. S.; Deng, C. X. BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr. Biol. 2004, 14, 2135–2142.; Wallace, W. H.; Thomson, A. B.; Kelsey, T. W. The radiosensitivity of the human oocyte. Hum. Reprod. 2003, 18, 117–121.; Saran, F.; Kelsey, T. W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 738–744.; Hodgson DC : Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011 : 323–329.; Ng AK : Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011, 154 (1) : 23–31.; Elkin EB, Klem ML, Gonzales AM, et al : Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma : a multi-institutional, matched cohort study. J Clin Oncol 2011, 29 (18) : 2466–2473.; Baker, T. G. Comparative aspects of the effects of radiation during oogenesis. Mutat. Res. 1971, 11, 9±22.; Donin N, Filson C, Drakaski A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016; 122 : 3075–3086.; Saletta F, Seng M and Lau L. Advances in pediatric cancer treatment. Transl Pediatr 3 (2) : 156–82. 4. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64 : 83–103.; Institute NC. Childhood Cancer by site incidence, survival and mortality 2019, April, https://seer.cancer.gov/csr/1975_2016/results_merged/sect_28_childhood_cancer.pdf.; Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer : a summary from the childhood cancer survivor study. J Clin Oncol 2009; 27 : 2328–2338.; Lee JS, Dubois SG, Coccia PF, et al. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer 2016; 122 : 116–123.; Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD : National Cancer Institute; 2015.; Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002; 94 : 182–192.; Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr. Second cancers following non-Hodgkin’s lymphoma. Cancer. 1991; 67 : 2002–2009.; Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors : SEER Cancer Registries, 1973–2000. Bethesda, MD : National Cancer Institute; 2006. NIH Pub. No. 05–5302.; Важенин А. В., Шаназаров Н. А., Шунько Е. Л. Некоторые закономерности развития радиоиндуцированных метахронных опухолей. Вестник рентгенологии и радиологии № 6, 2015. С 30–35.; Bertin F, Deluche E, Tricard J, Piccardo A, Denes E. First case of sternum replacement with a bioceramic prosthesis after radio-induced sarcoma. Curr Oncol. 2018 Aug; 25 (4) : e351-e353. doi:10.3747/co.25.4020. Epub 2018 Aug 14. PMID : 30111981; PMCID : PMC6092061.; Majdoubi A, Serji B, Harroudi TE. Angiosarcome mammaire radio-induit : à propos d’un cas [Radiation-induced breast angiosarcoma : about a case]. Pan Afr Med J. 2020 May 21; 36 : 29. French. doi:10.11604/pamj.2020.36.29.21599. PMID : 32774606; PMCID : PMC7388625.; Меньшиков К. В., Пушкарев А. В., Султанбаев А. В., Пушкарев В. А., Шарифгалиев И. А. Радиоиндуцированная ангиосаркома влагалища : клинический случай. Креативная хирургия и онкология. 2020; 10 (2) : 143–148. https://doi.org/10.24060/2076-3093-2020-10-2-143-148.; Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease : a population-based evaluation over 25 years. J Clin Oncol. 2002; 20 : 3484–94. DOI:10.1200/JCO. 2002.09.038.; Огнерубов Н. А., Антипова Т. С. Радиационно-индуцированная саркома мягких тканей шеи после лучевой терапии лимфомы Ходжкина. Клиническое наблюдение. Современная Онкология. 2022; 24 (3) : 325–330. DOI:10.26442/18151434.2022.3.201904.; van Eggermond AM, Schaapveld M, Lugtenburg PJ. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014; 124 (3) : 319–27. DOI:10.1182/blood-2013-10-532184.; Ng AK, Mauch PM. Late effects of Hodgkin’s disease and its treatment. Cancer J. 2009; 15 : 164–8. DOI:10.1097/PPO.0b013e31819e30d7.; Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease : a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988; 6 (2) : 239–252.; Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol Suppl. 2005; (66) : 135–140.; Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al; European Organisation for Research and Treatment of Cancer. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 2002; 38 (suppl 4) : S107-S113.; Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I–II Hodgkin’s disease 1963–1987. Recent Results Cancer Res. 1989; 117 : 175–181.; Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials : 1964–1987. Blood. 1989; 73 (1) : 47–56.; van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014 Jul 17; 124 (3) : 319–27; quiz 466. doi:10.1182/blood-2013-10-532184. Epub 2014 Apr 16. PMID : 24740811.; Cahan WG, Woodard HQ, Higinbotham NL, et al. Sarcoma in irradiated bone. Report of eleven cases. Cancer. 1948 : 3–29. DOI:10.1002/1097-0142(194805) 1 : 13.0. CO; 2–7.; Hall EJ, Wuu CS. Radiation-induced second cancers : the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003; 56 : 83–8. DOI:10.1016/S0360–3016 (03) 00073–7.; https://www.malignanttumors.org/jour/article/view/1142

الاتاحة: https://www.malignanttumors.org/jour/article/view/1142
https://doi.org/10.18027/2224-5057-2023-13-4-84-92

المؤلفون: G. A. Serebrennikov, К. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, D. O. Lipatov, A. Sh. Rezyapova, Г. А. Серебренников, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, Д. О. Липатов, А. Ш. Резяпова

المساهمون: This work is not funded, Данная работа не финансировалась

المصدر: Creative surgery and oncology; Том 13, № 2 (2023); 131-142 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 131-142 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: ингибиторы иммунных контрольных точек, liver neoplasms, clinical practice, atezolizumab, bevacizumab, clinical trials, randomized controlled clinical trial, immune checkpoint inhibitors, новообразования печени, клиническая практика, атезолизумаб, бевацизумаб, клинические исследования, рандомизированное контролируемое клиническое исследование

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/810/547; Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380 (15): 1450–62. DOI:10.1056/NEJMra1713263; Ахметгареева К. Т., Липатов О. Н., Меньшиков К. В., Султанбаев А. В. Заболеваемость первичным раком печени в Республике Башкортостан. В кн.: Белые ночи 2020 : тезисы VI Петербургского международного онкологического форума. СПб; 2020. С. 22.; Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017; 1018: 11–21. DOI:10.1007/978-981-10-5765-6_2; Kanwal F., Kramer J. R., Mapakshi S., Natarajan Y., Chayanupatkul M., Richardson P. A., et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018; 155 (6): 1828–37.e2. DOI:10.1053/j.gastro.2018.08.024; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Рахматуллина И. Р., Меньшикова И. А., Абдеев Р. Р. и др. Гепатоцеллюлярная карцинома: этиологические факторы и механизмы развития. Обзор литературы. Креативная хирургия и онкология. 2022; 12 (2): 139–50. DOI:10.24060/2076-3093-2022-12-2-139-150; Llovet J. M., Villanueva A., Lachenmayer A., Finn R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015; 12 (7): 408–24. DOI:10.1038/nrclinonc.2015.103; Cheng A. L., Kang Y. K., Chen Z., Tsao C. J., Qin S., Kim J. S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. DOI:10.1016/S1470-2045(08)70285-7; Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359 (4): 378–90. DOI:10.1056/NEJMoa0708857; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Меньшикова И. A., Абдеев Р. Р., Султанбаева Н. И. и др. Иммунотерапия распространенной гепатоцеллюлярной карциномы : обзор литературы и клинический случай. Медицинский совет. 2022; 16 (9): 31–9. DOI:10.21518/2079-701X-2022-16-9-31-39; Kudo M., Finn R. S., Qin S., Han K. H., Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391 (10126): 1163–73. DOI:10.1016/S0140-6736(18)30207-1; Bruix J., Qin S., Merle P., Granito A., Huang Y. H., Bodoky G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. DOI:10.1016/S0140-6736(16)32453-9; Меньшиков К. В., Султанбаев А. В., Ахметгареева К. Т., Липатов Д. О. Лечение метастатического гепатоцеллюлярного рака ленватинибом. Клинический случай и обзор литературы. Современная онкология. 2021; 23 (1): 156–61. DOI:10.26442/18151434.2021.1.200785; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1): 182–236. DOI:10.1016/j.jhep.2018.03.019; Heimbach J. K., Kulik L. M., Finn R. S., Sirlin C. B., Abecassis M. M., Roberts L. R., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 (1): 358–80. DOI:10.1002/hep.29086; Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122 (3): 664–71. DOI:10.1002/ijc.23131; Tamai T., Hayato S., Hojo S., Suzuki T., Okusaka T., Ikeda K., et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017; 57 (9): 1138–47. DOI:10.1002/jcph.917; Finn R. S., Ikeda M., Zhu A. X., Sung M. W., Baron A. D., Kudo M., et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020; 38 (26): 2960–70. DOI:10.1200/JCO.20.00808; Pishvaian M. J., Lee M. S., Ryoo B.-Y., Stein S., Lee K-H., Verret W., et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 2018; 29 (Suppl.8): 718–9.; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382 (20): 1894–905. DOI:10.1056/NEJMoa1915745; Giannini E. G., Aglitti A., Borzio M., Gambato M., Guarino M., Iavarone M., et al. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and The ITA.LI.CA Cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel). 2019;11(11):1689. DOI:10.3390/cancers11111689; Gordan J. D., Kennedy E. B., Abou-Alfa G. K., Beg M. S., Brower S. T., Gade T. P., et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38 (36): 4317–45. DOI:10.1200/JCO.20.02672; de Castro T., Jochheim L. S., Bathon M., Welland S., Scheiner B., Shmanko K., et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022; 14: 17588359221080298. DOI:10.1177/17588359221080298; Hatanaka T., Kakizaki S., Hiraoka A., Tada T., Hirooka M., Kariyama K., et al. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 2023; 12 (5): 5293–303. DOI:10.1002/cam4.5337; Shimose S., Hiraoka A., Nakano M., Iwamoto H., Tanaka M., Tanaka T., et al. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med. 2021; 10 (23): 8530–41. DOI:10.1002/cam4.4367; Hatanaka T., Kakizaki S., Nagashima T., Namikawa M., Ueno T., Tojima H., et al. Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study. Oncology. 2021; 99 (10): 641–51. DOI:10.1159/000517494; Tsuchiya K., Kurosaki M., Sakamoto A., Marusawa H., Kojima Y., Hasebe C., et al. The real-world data in japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel). 2021; 13 (11): 2608. DOI:10.3390/cancers13112608; Hiraoka A., Kumada T., Tada T., Tani J., Kariyama K., Fukunishi S., et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021; 11 (1): 16663. DOI:10.1038/s41598-021-96089-x; Tomonari T., Sato Y., Tanaka H., Mitsuhashi T., Hirao A., Tanaka T., et al. Th erapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021; 5 (11): 1275–83. DOI:10.1002/jgh3.12663; Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 (8): 646–9. DOI:10.1002/bjs.1800600817; Tada T., Kumada T., Hiraoka A., Hirooka M., Kariyama K., Tani J., et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med. 2022; 11 (20): 3796–808. DOI:10.1002/cam4.4763; Singal A. G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72 (2): 250–61. DOI:10.1016/j.jhep.2019.08.025; Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017; 3 (12): 1683–91. DOI:10.1001/jamaoncol.2017.3055; Kumada T., Toyoda H., Tada T., Yasuda S., Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of child-pugh classification and albumin bilirubin grade. Liver Cancer. 2020; 9 (5): 518–28. DOI:10.1159/000507933; Johnson P. J., Berhane S., Kagebayashi C., Satomura S., Teng M., Reeves H. L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33 (6): 550–8. DOI:10.1200/JCO.2014.57.9151; Iwamoto H., Shimose S., Noda Y., Shirono T., Niizeki T., Nakano M., et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021; 13 (11): 2786. DOI:10.3390/cancers13112786; Finn R. S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020; 38 (3): 193–202. DOI:10.1200/JCO.19.01307; Yau T., Park J. W., Finn R. S., Cheng A. L., Mathurin P., Edeline J., et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022; 23 (1): 77–90. DOI:10.1016/S1470-2045(21)00604-5; Cheng A. L., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76 (4): 862–73. DOI:10.1016/j.jhep.2021.11.030; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T.-Y., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC). J Clin Oncol. 2021; 39 (3S): 267. DOI:10.1200/JCO.2021.39.3_suppl.267; Galle P. R., Finn R. S., Qin S., Ikeda M., Zhu A. X., Kim T. Y., et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (7): 991–1001. DOI:10.1016/S1470-2045(21)00151-0; Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228–47. DOI:10.1016/j.ejca.2008.10.026; Lencioni R., Llovet J. M. Modifi ed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30 (1): 52–60. DOI:10.1055/s-0030-1247132; Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda; 2009.; Common Terminology Criteria for Adverse Events (CTCAE). v.5.0; Cancer Therapy Evaluation Program (CTEP). Rockville; 2017.; Himmelsbach V., Pinter M., Scheiner B., Venerito M., Sinner F., Zimpel C., et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. Cancers (Basel). 2022; 14 (7): 1722. DOI:10.3390/cancers14071722; Qin S., Ren Z., Feng Y. H., Yau T., Wang B., Zhao H., et al. Atezolizumab plus bevacizumab versus sorafenib in the chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021; 10 (4): 296–308. DOI:10.1159/000513486; Pfister D., Núñez N. G., Pinyol R., Govaere O., Pinter M., Szydlowska M., et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592 (7854): 450–6. DOI:10.1038/s41586-021-03362-0; Inada Y., Mizukoshi E., Seike T., Tamai T., Iida N., Kitahara M., et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology. 2019; 69 (2): 653–65. DOI:10.1002/hep.30212; https://www.surgonco.ru/jour/article/view/810

الاتاحة: https://www.surgonco.ru/jour/article/view/810
https://doi.org/10.24060/2076-3093-2023-13-2-131-142

المؤلفون: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, A. A. Izmailov, A. A. Fatikhova, D. O. Lipatov, G. A. Serebrennikov, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, А. А. Измайлов, А. А. Фатихова, Д. О. Липатов, Г. А. Серебренников

المصدر: Creative surgery and oncology; Том 12, № 4 (2022); 309-319 ; Креативная хирургия и онкология; Том 12, № 4 (2022); 309-319 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: пембролизумаб, microsatellite instability, immunotherapy, chemotherapy, tyrosine kinase inhibitors, lenvatinib, pembrolizumab, микросателлитная нестабильность, иммунотерапия, химиотерапия, ингибиторы тирозинкиназ, ленватиниб

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/738/523; Сote M.L., Ruterbusch J.J., Olson S.H., Lu K., Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1407–15. DOI:10.1158/1055-9965.EPI-15-0316; Constantine G.D., Kessler G., Graham S., Goldstein S.R. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larchmt). 2019;28(2):237–43. DOI:10.1089/jwh.2018.6956; Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. DOI:10.1158/0008-5472. CAN-14-0155; Key statistics for endometrial cancer. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html.; Endometrial cancer survival rates, by stage. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html.; National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.; Miller D.S., Filiaci V.L., Mannel R.S., Cohn D.E., Matsumoto T., Tewari K.S., et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50. DOI:10.1200/JCO.20.01076; Меньшиков К.В., Султанбаев А.В., Мусин Ш.И., Меньшикова И.А., Липатов Д.О., Султанбаева Н.И. и др. Системная терапия распространенного рака эндометрия. Обзор литературы. Поволжский онкологический вестник. 2021;12(1):31–43.; Makker V., Green A.K., Wenham R.M., Mutch D., Davidson B., Miller D.S. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19. DOI:10.1186/s40661-017-0056-7; Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14(2):357–61. DOI:10.1200/JCO.1996.14.2.357; Keytruda (pembrolizumab). Whitehouse Station, NJ: Merck Sharp & Dohme; 2018.; Arora E., Masab M., Mittar P., Jindal V., Gupta S., Dourado C. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus. 2018;10(4):e2521. DOI:10.7759/cureus.2521; Bell D.W., Ellenson L.H. Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 2019;14:339–67. DOI:10.1146/annurevpathol-020117-043609; O’Malley D.M., Bariani G.M., Cassier P.A., Marabelle A., Hansen A.R., De Jesus Acosta A., et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61. DOI:10.1200/JCO.21.01874; Marabelle A., Le D.T., Ascierto P.A., Di Giacomo A.M., De JesusAcosta A., Delord J.P., et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. DOI:10.1200/JCO.19.02105; Soumerai T.E., Donoghue M.T.A., Bandlamudi C., Srinivasan P., Chang M.T., Zamarin D., et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–47. DOI:10.1158/1078-0432.CCR-18-0412; Ott P.A., Bang Y.J., Berton-Rigaud D., Elez E., Pishvaian M.J., Rugo H.S., et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41. DOI:10.1200/JCO.2017.72.5952; Suyama K., Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361. DOI:10.1177/1073274818789361; Okamoto K., Kodama K., Takase K., Sugi N.H., Yamamoto Y., Iwata M., et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. DOI:10.1016/j.canlet.2013.07.007; Ferrari S.M., Ruffilli I., Centanni M., Virili C., Materazzi G., Alexopoulou M., et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–8. DOI:10.2174/1574892813666180220110729; Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026; Vergote I., Powell M.A., Teneriello M.G., Miller D.S., Garcia A.A., Mikheeva O.N., et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020;156(3):575–82. DOI:10.1016/j.ygyno.2019.12.039; Kato Y., Tabata K., Kimura T., Yachie-Kinoshita A., Ozawa Y., Yamada K., et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. DOI:10.1371/journal.pone.0212513; Kato Y., Bao X., Macgrath S., Tabata K., Hori Y., Tachino S., et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol. 2016;27(suppl 6): abstr 2PD. DOI:10.1093/annonc/mdw362.02; Kimura T., Kato Y., Ozawa Y., Kodama K., Ito J., Ichikawa K., et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993–4002. DOI:10.1111/cas.13806; Taylor M., Dutcus C.E., Schmidt E., Bagulho T., Li D., Shumaker R., et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol. 2016;27(suppl 6): abstr 776PD. DOI:10.1093/annonc/mdw373.04; Makker V., Rasco D., Vogelzang N.J., Brose M.S., Cohn A.L., Mier J., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8. DOI:10.1016/S1470-2045(19)30020-8; Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–92. DOI:10.1200/JCO.19.02627; Oaknin A., Duska L.R., Sullivan R.J., Pothuri B., Ellard S.L., Leath C.A. III, et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol. 2019;154(suppl 1): abstr 33. DOI:10.1016/j.ygyno.2019.04.044; Konstantinopoulos P.A., Luo W., Liu J.F., Gulhan D.C., Krasner C., Ishizuka J.J., et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94. DOI:10.1200/JCO.19.01021; Antill Y., Kok P.S., Robledo K., Yip S., Cummins M., Smith D., et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):e002255. DOI:10.1136/jitc-2020-002255; Aghajanian C., Sill M.W., Darcy K.M., Greer B., McMeekin D.S., Rose P.G., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. DOI:10.1200/JCO.2010.32.6397; Spirtos N.M., Enserro D., Homesley H.D., Gibbons S.K., Cella D., Morris R.T., et al. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2019 Jul;154(1):13–21. doi:10.1016/j.ygyno.2019.03.240; Motzer R.J., Hutson T.E., Glen H., Michaelson M.D., Molina A., Eisen T., et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9; Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. DOI:10.1056/NEJMoa1503093; Schlumberger M., Tahara M., Wirth L.J., Robinson B., Brose M.S., Elisei R., et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470; Marcus L., Lemery S.J., Keegan P., Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–8. DOI:10.1158/1078-0432.CCR-18-4070; Marth C., Tarnawski R., Tyulyandina A., Pignata S., Gilbert L., Kaen D., et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93–100. DOI:10.1136/ijgc-2021-003017; Makker V., Colombo N., Casado Herráez A., Santin A.D., Colomba E., Miller D.S., et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. DOI:10.1056/NEJMoa2108330; McMeekin S., Dizon D., Barter J., Scambia G., Manzyuk L., Lisyanskaya A., et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23. DOI:10.1016/j.ygyno.2015.04.026; Miller D.S., Scambia G., Bondarenko I., Westermann A.M., Oaknin A., Oza A.M., et al. ZoptEC: phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer. J Clin Oncol. 2018;36(Suppl 15):5503. DOI:10.1200/JCO.2018.36.15_suppl.5503; Fala L. Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer. Am Health Drug Benefits. 2015;8(Spec Feature):176–9. PMID: 26629286; Robert C., Ribas A., Schachter J., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. DOI:10.1016/S1470-2045(19)30388-2; How J.A., Patel S., Fellman B., Lu K.H., Hwu P., Ramondetta L.M., et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021;162(1):24–31. DOI:10.1016/j.ygyno.2021.04.034; Pal S.K., Puente J., Chin Heng D.Y., Glen H., Koralewski P., Stroyakovskiy D., et al. Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC). Kidney Cancer J. 2020;18(Suppl 4):34–5. DOI:10.1200/JCO.2021.39.6_suppl.307; Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G.M., Gianoukakis A.G., et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107(3):776–87. DOI:10.1210/clinem/dgab731; https://www.surgonco.ru/jour/article/view/738

الاتاحة: https://www.surgonco.ru/jour/article/view/738
https://doi.org/10.24060/2076-3093-2022-12-4-309-319

المؤلفون: Sh. I. Musin, A. V. Sultanbaev, K. V. Menshikov, L. K. Zakirova, F. F. Mufazalov, I. A. Sharifgaliev, A. F. Nasretdinov, S. V. Osokin, N. A. Sharafutdinova, V. V. Ilyin, D. O. Lipatov, M. V. Sultanbaev, T. E. Timin, Ш. И. Мусин, А. В. Султанбаев, К. В. Меньшиков, Л. К. Закирова, Ф. Ф. Муфазалов, И. А. Шарифгалиев, А. Ф. Насретдинов, С. В. Осокин, Н. А. Шарафутдинова, В. В. Ильин, Д. О. Липатов, М. В. Султанбаев, К. Е. Тимин

المصدر: Creative surgery and oncology; Том 12, № 4 (2022); 267-274 ; Креативная хирургия и онкология; Том 12, № 4 (2022); 267-274 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: иммуногистохимия, human papillomavirus, HPV associations, p16, squamous cell carcinoma, adenocarcinoma, sarcoma, diagnostic and treatment tactics, immunohistochemistry, папилломавирус человека, ВПЧ-ассоциации, р16, плоскоклеточный рак, аденокарцинома, саркома, лечебно-диагностическая тактика

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/730/516; Pytynia K.B., Dahlstrom K.R., Sturgis E.M. Epidemiology of HPVassociated oropharyngeal cancer. Oral Oncol. 2014;50(5):380–6. DOI:10.1016/j.oraloncology.2013.12.019; Timbang M.R., Sim M.W., Bewley A.F., Farwell D.G., Mantravadi A., Moore M.G. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7–8):1920–8. DOI:10.1080/21645515.2019.1600985; Каприн А.Д., Старинский В.В., Шахзадава А.О. (ред.) Состояние онкологической помощи населению России в 2020 году. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2021.; Мудунов А.М., Чойнзонов Е.Л., Решетов И.В. и др. Рак ротоглотки: Клинические рекомендации. М., 2020.; Machczyński P., Majchrzak E., Niewinski P., Marchlewska J., Golusiński W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277(9):2407–12. DOI:10.1007/s00405-020-05979-9; Mehanna H., Beech T., Nicholson T., El-Hariry I., McConkey C., Paleri V., et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and metaanalysis of trends by time and region. Head Neck. 2013;35(5):747–55. DOI:10.1002/hed.22015; Карпенко А. В., Сибгатуллин Р. Р., Бойко А. А., Воробьев С.Л., Кораблина И.М., Николаева О.М. и др. Частота встречаемости и прогноз ВПЧ-позитивного рака ротоглотки. Онкология. Журнал им. П.А. Герцена. 2019;8(1):20–5. DOI:10.17116/onkolog2019801120; Стукань А.И., Чухрай О.Ю., Порханов В.А., Мурашко Р.А., Бодня В.Н., Элизбарян И.С. Клинико-морфологические и прогностические особенности плоскоклеточного рака органов головы и шеи, ассоциированного с вирусом папилломы человека. Онкология. Журнал им. П.А. Герцена. 2019;8(1):13–9. DOI:10.17116/onkolog2019801113; Пхешхова Б.Г., Мудунов А.М., Азизян Р.И., Пак М.Б., Ищенко К.Б. Оценка распространенности ВПЧ-положительного плоскоклеточного рака ротоглотки на примере отдельной выборки в Российской Федерации. Опухоли головы и шеи. 2022;12(1):72–8. DOI; 17650/2222-1468-2022-12-1-72-78 10 Nauta I.H., Riebergen M.M., van Bokhoven A.A.J.D., Bloemena E., Lissenberg-Witte B.I., Heideman D.A.M., et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29(5):1273–79. DOI:10.1093/annonc/mdy060. PMID: 29438466; Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82. DOI:10.1038/nature14129; Yakin M., Seo B., Hussaini H., Rich A., Hunter K. Human papillomavirus and oral and oropharyngeal carcinoma: the essentials. Aust Dent J. 2019;64(1):11–8. DOI:10.1111/adj.12652; Machiels J.P., René Leemans C., Golusinski W., Grau C., Licitra L., Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75. DOI:10.1016/j.annonc.2020.07.011; Tawk B., Debus J., Abdollahi A. Evolution of a paradigm switch in diagnosis and treatment of HPV-driven head and neck cancer-striking the balance between toxicity and cure. Front Pharmacol. 2022;12:753387. DOI:10.3389/fphar.2021.753387; Malm I.J., Fan C.J., Yin L.X., Li D.X., Koch W.M., Gourin C.G., et al. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Cancer. 2017;123(10):1768–77. DOI:10.1002/cncr.30512; Nichols A.C., Theurer J., Prisman E. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349–59. DOI:10.1016/S1470-2045 (19)30410-3; Tiedemann D., Jakobsen K.K., von Buchwald C., Grønhøj C. Systematic review on location and timing of distant progression in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. Head Neck. 2019;41(3):793–8. DOI:10.1002/hed.25458; https://www.surgonco.ru/jour/article/view/730

الاتاحة: https://www.surgonco.ru/jour/article/view/730
https://doi.org/10.24060/2076-3093-2022-12-4-267-274

المؤلفون: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, A. A. Izmailov, V. S. Chalov, I. A. Menshikova, N. I. Sultanbaeva, E. V. Popova, D. O. Lipatov, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, А. A. Измайлов, В. С. Чалов, И. А. Меньшикова, Н. И. Султанбаева, Е. В. Попова, Д. О. Липатов

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 85-92 ; Медицинский Совет; № 9 (2022); 85-92 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: нежелательные явления, tyrosine kinase inhibitors, sunitinib, alternative dosing regimens, dose reduction, adverse events, ингибиторы тирозинкиназ, сунитиниб, альтернативные режимы дозирования, редукция доз

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6921/6218; Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471-478. Available at: https://pubmed.ncbi.nlm.nih.gov/12748309/.; Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337. Available at: https://pubmed.ncbi.nlm.nih.gov/12538485/.; O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597-3605. https://doi.org/10.1182/blood-2002-07-2307.; Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24. https://doi.org/10.1200/JCO.2005.02.2574.; Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-2524. https://doi.org/10.1001/jama.295.21.2516.; Калпинский А.С., Алексеев Б.Я. Эффективность Сунитиниба в таргетной терапии метастатического рака почки. Онкоурология. 2009;(3):63-67. Режим доступа: https://oncourology.abvpress.ru/oncur/article/view/272.; Najjar Y.G., Mittal K., Elson P., Wood L., Garcia J.A., Dreicer R., Rini B.I. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084-1089. https://doi.org/10.1016/j.ejca.2014.01.025.; Jonasch E., Slack R.S., Geynisman D.M., Hasanov E., Milowsky M.I., Rathmell W.K. et al. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018;36(16):1588-1593. https://doi.org/10.1200/JCO.2017.77.1485.; Bjarnason G.A., Knox J.J., Kollmannsberger C.K., Soulieres D., Ernst D.S., Zalewski P. et al. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. J Clin Oncol. 2019;108:69-77. https://doi.org/10.1016/j.ejca.2018.12.006.; Lee J.L., Kim M.K., Park I., Ahn J.-H., Lee D.H., Ryoo H.M. et al. Randomized phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26(11):2300-2305. https://doi.org/10.1093/annonc/mdv357.; Bracarda S., Iacovelli R., Boni L., Rizzo M., Derosa L., Rossi M. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107-2713. https://doi.org/10.1093/annonc/mdv315.; Kalra S., Rini B.I., Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1300-1304. https://doi.org/10.1093/annonc/mdv030.; Kondo T., Takagi T., Kobayashi H., Iizuka J., Nozaki T., Hashimoto Y. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma - comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol. 2014;44(3):270-277. https://doi.org/10.1093/jjco/hyt232.; Atkinson B.J., Kalra S., Wang X., Bathala T., Corn P., Tannir N.M., Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611-618. https://doi.org/10.1016/j.juro.2013.08.090.; Neri B., Vannini A., Brugia M., Muto A., Rangan S., Rediti M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol. 2013;20(5):478-483. https://doi.org/10.1111/j.1442-2042.2012.03204.x.; Bjarnason G.A., Khalil B., Hudson J.M., Williams R., Milot L.M., Atri M. et al. Outcomes in patients with metastatic renal cell cancer treated with individ-ualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32(4):480-487. https//doi.org/10.1016/j.urolonc.2013.10.004.; Bracarda S., Sisani M., Marrocolo F., Hamzaj A., del Buono S., De Simone V. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol. 2014;89(3):386-393. https://doi.org/10.1016Zj.critrevonc.2013.09.002.; Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(Suppl. 2):32-44. https://doi.org/10.1634/theoncologist.2011-S2-32.; Mouillet G., Paillard M.-J., Maurina T., Vernerey D., Hon T.N.T., Almotlak H. et. al. Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial. Trials. 2018;19(1):221. https://doi.org/10.1186/s13063-018-2613-8.; Волкова М.И., Калинин С.А. Осталось ли место сунитинибу в современных рекомендациях по системному лечению распространенного почечноклеточного рака? Медицинский совет. 2021;(9):89-94. https//doi.org/10.21518/2079-701X-2021-9-89-94.; Ravaud A., Motzer R.J., Pandha H.S., George D.J., Pantuck A.J., Patel A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246-2254. https://doi.org/10.1056/NEJMoa1611406.; Mejean A., Ravaud A., Thezenas S., Colas S., Beauval J.-B., Bensalah K. et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018;379(5):417-427. https://doi.org/10.1056/NEJMoa1803675.; Матвеев В.Б., Маркова А.С. Рак почки: что нового в 2018 году. Онкоурология. 2018;14(4):48-52. https//doi.org/10.17650/1726-9776-2018-14-4-48-52.; Ljungberg B., Albiges L., Abu-Ghanem Y., Bensalah K., Dabestani S., Fernandez-Pello S. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799-810. https://doi.org/10.1016/j.eururo.2019.02.011.; Antonelli A., Minervini A., Sandri M., Bertini R., Bertolo R., Carini M. et al. Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Eur Urol. 2018;74(5):661-667. https//doi.org/10.1016/j.eururo.2018.07.029.; Меньшиков К.В., Измайлов А.А., Султанбаев А.В., Мусин Ш.И., Чалов В.С., Меньшикова И.А. и др. Метастатический почечно-клеточный рак, возможности таргетной терапии. Медицинский совет. 2021;(20):138-144. https://doi.org/10.21518/2079-701X-2021-20-138-144.; Bracarda S., Negrier S., Casper J., Porta C., Schmidinger M., Larkin J. et al. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2017;17(3):227-233. https://doi.org/10.1080/14737140.2017.1276830.; https://www.med-sovet.pro/jour/article/view/6921

الاتاحة: https://www.med-sovet.pro/jour/article/view/6921
https://doi.org/10.21518/2079-701X-2022-16-9-85-92

المؤلفون: K. V. Menshikov, A. V. Sultanbaev, A. A. Izmailov, Sh. I. Musin, I. A. Menshikova, V. S. Chalov, N. I. Sultanbaeva, D. O. Lipatov, К. В. Меньшиков, А. В. Султанбаев, А. А. Измайлов, Ш. И. Мусин, И. А. Меньшикова, В. С. Чалов, Н. И. Султанбаева, Д. О. Липатов

المصدر: Malignant tumours; Том 12, № 2 (2022); 45-51 ; Злокачественные опухоли; Том 12, № 2 (2022); 45-51 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: ниволумаб, tyrosine kinase inhibitors, checkpoint inhibitors, cabozantinib, nivolumab, ингибиторы тирозинкиназ, ингибиторы контрольных точек, кабозантиниб

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/962/682; Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68 (6):394–424. doi:10.3322/caac.21492. Epub 2018 Sep 12.; Измайлов А. А., Аюпов Р. Т., Сулатнбаев А. В., Мусин Ш. И., Меньшиков К. В., Забелин М. В. Организация работы онкологической службы в Республике Башкортостан в условиях пандемии COVID-19. Современные проблемы здравоохранения и медицинской статистики 2020 г., № 3. C. 195-208. DOI:10.24411/2312-2935-2020-00067.; Состояние онкологической помощи населению России в 2021 году. Под редакцией Каприна А. Д., Старинского В. В., Шахазадовой А. О.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 239 с. ISBN 978-5-85502-262-9.; Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354-66.; McKay RR, Bosse D, Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. J Clin Oncol 2018 October 29 (Epub ahead of print).; Heidegger I, Pircher A, Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 2019;9:490.; Apolo AB, Nadal R, Girardi DM, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 2020;38:3672-84.; Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer 2018;6:109.; Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116-27.; Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103-15.; Agarwal N, Vaishampayan U, Green M, et al. Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: results of the dose escalation stage in patients (pts) with treatmentnaive advanced renal cell carcinoma (RCC). J Clin Oncol 2020;29: Suppl 8:872P. abstract.; Pal S, Tsao C-K, Suarez C, et al. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. Ann Oncol 2020;31: Suppl 4: S554. abstract.; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Измайлов А. А., Меньшикова И. А., Хамматова Л. А., Попова Е. В., Султанбаева Н. И., Липатов Д. О. Вторая линия терапии метастатического почечноклеточного рака. Обзор литературы. Поволжский онкологический вестник. Том 12, № 4. 2021 С. 39-52.; Меньшиков К. В., Измайлов А. А., Султанбаев А. В., Мусин Ш. И., Чалов В. С., Меньшикова И. А., Султанбаева Н. И., Липатов Д. О. Метастатический почечно-клеточный рак, возможности таргетной терапии. Медицинский Совет. 2021; (20):138-144. https://doi.org/10.21518/2079-701X-2021-20-138-144.; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Рахматуллина И. Р., Меньшикова И. А., Хамматова Л. А., Попова Е. В., Султанбаева Н. И., Липатов Д. О. Возможности комбинированной иммунотаргетной терапии метастатического почечно-клеточного рака. Обзор литературы. Поволжский онкологический вестник. Том 13, № 1. 2022. С. 46-61.; Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.; Schmidt E, Lister J, Neumann M, et al. Cabozantinib versus standard-of-care comparators in the treatment of advanced/ metastatic renal cell carcinoma in treatment-naive patients: a systematic review and network meta-analysis. Target Oncol 2018;13:205-16.; Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591-7.; Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol 2016;17: 917-27.; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Измай лов А. A., Мугинов Р. Р., Меньшикова И. А., Шарифгалеев И. А., Липатов Д. О., Султанбаева Н. И. Почечно-клеточный рак с метастазами в наружных половых органах. Обзор литературы и клинический случай. Онкоурология. 2021;17 (2):174-181. https://doi.org/10.17650/1726-9776-2021-17-2-174-181.; Saeed A, Phadnis M, Park R, et al. Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results. J Clin Oncol 2020; 38: Suppl:4563. abstract.; Bergerot P, Lamb P, Wang E, Pal SK. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther 2019;18:2185-93.; Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017;543:728-32.; Apolo AB, Nadal R, Tomita Y, et al. Cabozantinib in patients with platinumrefractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol 2020;21:1099-109.; Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.; Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a populationbased study. Lancet Oncol 2013;14:141-8.; Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juarez VM, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 Mar 4;384 (9):829-841. doi:10.1056/NEJMoa2026982. PMID: 33657295; PMCID: PMC8436591.; Носов Д. А., Б. Я. Алексеев, Гладков О. А., Волкова М. И., Попов А. М., Харкевич Г. Ю. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2021 (том 11). 31. 10.18027/2224-5057-2021-11-3s2-31.; Aeppli S, Schmaus M, Eisen T, Escudier B, Grunwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini BI, Schmidinger M, Sternberg CN, Rothermundt C, Putora PM. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 2021 Feb;6 (1):100030. doi:10.1016/j.esmoop.2020.100030. Epub 2021 Jan 15. PMID: 33460963; PMCID: PMC7815472.; McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014;66 (3):502e9.; Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol 2016; 34 (27):3267e75; https://www.malignanttumors.org/jour/article/view/962

الاتاحة: https://www.malignanttumors.org/jour/article/view/962
https://doi.org/10.18027/2224-5057-2022-12-2-45-51

المؤلفون: L. I. Bashirova, A. S. Safonov, R. R. Kamilova, D. O. Lipatov, A. A. Bakirov, A. V. Samorodov

المصدر: Креативная хирургия и онкология, Vol 12, Iss 1, Pp 81-86 (2022)

مصطلحات موضوعية: рак яичников, нутритивный статус, оценка питания, недостаточное питание, послеоперационные осложнения, нутриенты, энтеральное питание, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/679; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/652fa1a333d840a5987cfd4f4bea3e56

الاتاحة: https://doi.org/10.24060/2076-3093-2022-12-1-81-86
https://doaj.org/article/652fa1a333d840a5987cfd4f4bea3e56

المؤلفون: A. Sultanbaev V., A. Nasretdinov F., N. Sultanbaeva I., K. Menshikov V., Sh. Musin I., A. Izmailov A., O. Lipatov N., V. Pushkarev A., R. Valiakhmedov B., A. Pushkarev V., F. Mufazalov F., А. Султанбаев В., А. Насретдинов Ф., Н. Султанбаева И., К. Меньшиков В., Ш. Мусин И., А. Измайлов А., О. Липатов Н., В. Пушкарев А., Р. Валиахмедов Б., А. Пушкарев В., Ф. Муфазалов Ф.

المساهمون: Исследование не имело спонсорской поддержки.

المصدر: Malignant tumours; Том 10, № 4 (2020); 38-46 ; Злокачественные опухоли; Том 10, № 4 (2020); 38-46 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: uterine cancer, breast cancer, luminal A subtype, palbociclib, ribociclib, рак тела матки, рак молочной железы, люминальный A подтип, палбоциклиб, рибоциклиб

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/816/571; Насретдинов А. Ф., Султанбаева Н. И., Мусин Ш. И. и др. Терапия ингибиторами циклинзависимых киназ CDK4/6 при разных спектрах соматических мутаций гена PIK3CA у больных раком молочной железы. Медицинский совет. 2020; (20):40-46. doi: 10.21 518/2079-701X-2020-20-40-46.; Sultanbaev, A. & Minniakhmetov, I. & Sultanbaeva, N. & Menshikov, K. & Nasretdinov, A. & Musin, S. (2020). 25P Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia. Annals of Oncology. 31. S1250. https://doi.org/10.1016/j. annonc. 2020.10.045.; Состояние онкологической помощи населению России в 2019 году. Под. ред. А. Д. Каприна, В. В. Старинского, А. О. Шахазадовой. М.: МНИОИ им. П. А. Герцена. 2020; 239 с. [Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossiiv 2019 godu. (The status of cancer care for the population of Russia in 2019.) A. D. Kaprin, V. V. Starinskiy, A. O. Shahazadova eds. М.: MNIIOI named by P. A. Herzen. 2020; 239 р. (In Russ.)]; Насретдинов А. Ф., Султанбаева Н. И., Мусин Ш. И. и др. Уровень опухоль-инфильтрирующих лимфоцитов и PD-статус как возможные прогностические маркеры выживаемости и эффективности терапии при трижды негативном раке молочной железы. Опухоли женской репродуктивной системы. 2020. Т. 16. № 1. С. 65-70. https:// doi.org/10.17 650/1994-4098-2020-16-1-65-70.; Wangchinda P., Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Onc. 2016;14:223. doi:10.1186/s12 957-016-0988-0. 7.; Ye J., Wang W., Xin L. et al. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China. Anticancer Res. 2017;37 (8):4549-4556. doi: 10.21 873/anticanres. 11 852.; Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66 (1):7-30. doi:10.3322/caac. 21 332.; Rossi V., Berchialla P., Giannarelli D. et al. Should All Patients With HR-Positive HER2‑Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel). 2019;11 (11):1661. doi:10.3390/cancers11 111 661.; Султанбаев А. В., Насретдинов А. В., Мусин Ш. И. и др. Эффективность гормонотерапии больных раком молочной железы при наличии мутации в гене PIK3СА. Евразийский онкологический журнал. 2020. Т. 8, № 2. Приложение. С21.; Thill, M., & Schmidt, M. (2018). Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitorbased treatment in breast cancer. Therapeutic advances in medical oncology, 10, 1 758 835 918 793 326. https://doi.org/10.1177/1 758 835 918 793 326; García-Trevijano Cabetas, M., Lucena Martínez, P., Jiménez Nácher, I. et al. (2020). Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. International journal of clinical pharmacy, 10.1007/s11 096-020-01 193‑z. Advance online publication. https://doi.org/10.1007/s11 096-020-01 193‑z; Pandey, K., An, H. J., Kim, S. K. et al. (2019). Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International journal of cancer, 145 (5), 1179-1188. https://doi.org/10.1002/ijc. 32 020; Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., Mulford, I., Acker, M. G., Chopra, R., Brain, C., di Tomaso, E., Sellers, W. R., & Caponigro, G. (2018). The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget, 9 (81), 35 226-35 240. https://doi.org/10.18 632/oncotarget. 26 215; Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016 Oct;15 (10):2273-2281. doi:10.1158/1535-7163. MCT-16-0300. Epub 2016 Aug 5. PMID: 27 496 135; Wander SA, Zangardi M, Niemierko A, et al: A multicenter analysis of abemaciclib after progression on palbociclib in patients with hormone receptor-positive/HER2 - metastatic breast cancer. 2019 ASCO Annual Meeting. Abstract 1057. Presented June 2, 2019 DOI:10.1200/JCO. 2019.37.15_suppl. 1057; Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., Burris, H. A., 3rd, Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., & Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2‑negative advanced breast cancer: overall survival results from BOLERO-2†. Annals of oncology: official journal of the European Society for Medical Oncology, 25 (12), 2357-2362. https://doi.org/10.1093/annonc/mdu456; Cook M, Al Rabadi L, Mitri ZI, et al: Everolimus and exemestane for the treatment of metastatic hormone receptorpositive breast cancer patients previously treated with CDK4/6 inhibitor-based therapies. 2019 ASCO Annual Meeting. Abstract 1058. Presented June 2, 2019 DOI:10.1200/JCO. 2019.37.15_suppl. 1058; https://www.malignanttumors.org/jour/article/view/816

الاتاحة: https://www.malignanttumors.org/jour/article/view/816
https://doi.org/10.18027/2224-5057-2020-10-3

المؤلفون: K. V. Menshikov, A. A. Izmailov, A. V. Sultanbaev, Sh. I. Musin, V. S. Chalov, I. A. Menshikova, N. I. Sultanbaeva, D. O. Lipatov

المصدر: Медицинский совет, Vol 0, Iss 20, Pp 138-144 (2021)

مصطلحات موضوعية: renal cell carcinoma, tyrosine kinase inhibitors, sunitinib, good prognosis group, first line of therapy, Medicine

Relation: https://www.med-sovet.pro/jour/article/view/6591; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790; https://doaj.org/article/1459d6c54dde4f2e9d9f808dc592a8e9

الاتاحة: https://doi.org/10.21518/2079-701X-2021-20-138-144
https://doaj.org/article/1459d6c54dde4f2e9d9f808dc592a8e9

المؤلفون: Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Kamila T. Akhmetgareeva, Danila O. Lipatov

المصدر: Современная онкология, Vol 23, Iss 1, Pp 156-161 (2021)

مصطلحات موضوعية: hepatocellular cancer, targeted therapy, lenvatinib, efficacy, tolerance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://modernonco.orscience.ru/1815-1434/article/viewFile/70477/51397; https://doaj.org/toc/1815-1434; https://doaj.org/toc/1815-1442; https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5

الاتاحة: https://doi.org/10.26442/18151434.2021.1.200785
https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5

المؤلفون: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, A. A. Izmaylov, R. R. Muginov, I. A. Menshikova, I. A. Sharifgaleev, D. O. Lipatov, N. I. Sultanbaeva

المصدر: Onkourologiâ, Vol 17, Iss 2, Pp 174-181 (2021)

مصطلحات موضوعية: renal cell carcinoma, metastasis to the external genital organs, sanitation vulvectomy, palliative nephrectomy, tyrosine kinase inhibitor, cabozantinib, Medicine

Relation: https://oncourology.abvpress.ru/oncur/article/view/1469; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/fad37e7d4d7241b8844bb73f933507d0

الاتاحة: https://doi.org/10.17650/1726-9776-2021-17-2-174-181
https://doaj.org/article/fad37e7d4d7241b8844bb73f933507d0

المؤلفون: A. Nasretdinov F., N. Sultanbaeva I., Sh. Musin I., O. Lipatov N., A. Izmailov A., R. Ayupov T., K. Menshikov V., A. Pushkarev V., A. Sultanbaev V., А. Насретдинов Ф., Н. Султанбаева И., Ш. Мусин И., О. Липатов Н., А. Измайлов А., Р. Аюпов Т., К. Меньшиков В., А. Пушкарев В., А. Султанбаев В.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 40-46 ; Медицинский Совет; № 20 (2020); 40-46 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: endocrine therapy, metastatic cancer, breast, PIK3CA, luminal subtype, CDK4/6 inhibitors, alpelisib, гормонотерапия, метастатический рак, молочная железа, люминальный подтип, ингибиторы CDK4/6, алпелисиб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5933/5417; Александрова Г.А., Голубев Н.А., Тюрина Е.М., Огрызко Е.В., Залевская О.В., Авдеева Л.Н. Социально значимые заболевания населения России в 2018 году. М.; 2019. 73 с. Режим доступа: :https://static-0.rosminzdrav.ru/system/attachments/attaches/000/046/521/original/11_%D0%A1%D0%BE%D1%86%D0%B8%D0%B0%D0%BB%D1%8C%D0%BD%D0%BE-%D0%B7%D0%BD%D0%B0%D1%87%D0%B8%D0%BC%D1%8B%D0%B5_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BD%D0%B0%D1%81%D0%B5%D0%BB%D0%B5%D0%BD%D0%B8%D1%8F_%D0%A0%D0%BE%D1%81%D1%81%D0%B8%D0%B8_%D0%B2_2018_%D0%B3%D0%BE%D0%B4%D1%83.doc?1564572091.; Soerjomataram I., Louwman M.W., Ribot J.G., Roukema J.A., Coebergh J.W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–330. doi:10.1007/s10549-007-9556-1.; Wangchinda P., Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Onc. 2016;14:223. doi:10.1186/s12957-016-0988-0.; Ye J., Wang W., Xin L., Owen S., Xu L., Duan X. et al. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China. Anticancer Res. 2017;37(8):4549–4556. doi:10.21873/anticanres.11852.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin.2016;66(1):7–30. doi:10.3322/caac.21332.; Robertson J.F.R., Bondarenko I.M., Trishkina E., Dvorki M., Panasci, L., Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997– 3005. doi:10.1016/S0140-6736(16)32389-3.; Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Doubleblind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–3395. doi:10.1200/JCO.2002.10.058.; Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federicoet M. et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–1670. doi:10.1200/JCO.2007.13.5822.; Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. doi:10.1056/NEJMoa1109653.; Schettini F., De Santo I., Rea C.G., De Placido P., Formisano L., Giuliano M. et al. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol. 2018;8:608. doi:10.3389/fonc.2018.00608.; Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi:10.1016/S1470-2045(15)00613-0.; Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., PaluchShimon S. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. doi:10.1093/annonc/mdy155.; Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.6155.; Sledge G.W., Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875–2884. doi:10.1200/JCO.2017.73.7585.; Rossi V., Berchialla P., Giannarelli D., Nisticò C., Ferretti G., Gasparro S. et al. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel). 2019;11(11):1661. doi:10.3390/cancers11111661.; Im S.A., Lu Y.S., Bardia A., Harbeck N., Colleoni M., Franke K. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307–316. doi:10.1056/NEJMoa1903765.; Slamon D.J., Neven P., Chia S., Fasching P., De Laurentiis M., Im S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514–524. doi:10.1056/NEJMoa1911149.; Sledge G.W. Jr., Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone ReceptorPositive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy – MONARCH 2: a Randomized Clinical Trial. JAMA Oncol. 2019;6(1):116–124. doi:10.1001/jamaoncol.2019.4782.; Андреева Ю.Ю., Жукова Л.Г., Завалишина Л.Э., Закиряходжаев А.Д., Королева И.А., Назаренко А.В. и др. Рак молочной железы: клинические рекомендации. 2020. Режим доступа: http://cr.rosminzdrav.ru/#!/recomend/236.; Mangone F.R., Bobrovnitchaia I.G., Salaorni S., Manuli E., Nagai M. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo). 2012;67(11):1285–1290. doi.org/10.6061/clinics/2012(11)11.; O’Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A. et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3’ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670–3683. doi:10.1158/1078-0432.CCR-09-2828.; Mosele F., Stefanovska B., Lusque A., Tran Dien A., Garberis I., Droin N. et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377–386. doi:10.1016/j.annonc.2019.11.006.; Семиглазова Т.Ю., Сорокина И.В. Прогностическое и предиктивное значения мутации гена PIK3CA у больных раком молочной железы. Фарматека. 2019;26(7):10–20. doi:10.18565/pharmateca.2019.7.10-20.; Семиглазова Т.Ю., Семиглазов В.В., Клименко В.В., Бриш Н.А., Алексеева Ю.В., Клюге В.А. и др. Применение алпелисиба для лечения HR+/HER2метастатического рака молочной железы у пациентов с мутацией PIK3CA: результаты исследования SOLAR-1. Фарматека. 2020;(7):15–23. doi:10.18565/pharmateca.2020.7.15-23; Andre F., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904.; Neven P., Petrakova K., Val Bianchi G., De la Cruz-Merino L., Jerusalem G., Sonke G. et al. Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study. Cancer Res. 2019;79(4S):PD2–05. doi:10.1158/1538-7445.SABCS18-PD2-05.; Juric D., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S. et al. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial results. Cancer Res. 2019;79(4S):GS3-08. doi:10.1158/1538-7445.SABCS18-GS3-08.; Rugo H., Lerebours F., Ciruelos E., Drullinsky P., Ruiz Borrego M., Neven P. et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclindependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J Clin Oncol. 2020;38(15S):1006. doi:10.1200/JCO.2020.38.15_suppl.1006.; https://www.med-sovet.pro/jour/article/view/5933

الاتاحة: https://www.med-sovet.pro/jour/article/view/5933
https://doi.org/10.21518/2079-701X-2020-20-40-46

المؤلفون: O. Lipatov N., K. Akhmetgareeva T., О. Липатов Н., К. Ахметгареева Т.

المصدر: Creative surgery and oncology; Том 10, № 4 (2020); 330-338 ; Креативная хирургия и онкология; Том 10, № 4 (2020); 330-338 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: malignant neoplasms, prevention, genetic susceptibility to disease, genetic testing, mutagenicity tests, EGFR genes, BRCA1 genes, BRCA 2 genes, TP53 genes, RET genes, microsatellite instability, злокачественные новообразования, профилактика, генетическая предрасположенность к болезни, генетическое тестирование, мутагенности тесты, гены EGFR, гены BRCA1, гены BRCA 2, гены TP53, гены RET, микросателлитная нестабильность

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/537/428; Каприн А.Д., Старинский В.В., Шахзадова А.О. Cостояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.; Sokolenko A.P., Imyanitov E.N. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018;5:76. DOI:10.3389/fmolb.2018.00076; Cancer: Fact Sheet No 297. WHO [cited 2015 March 20]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/; Lichtenstein P., Holm N.V., Verksalo P.K., Iliadou A., Kaprio J., Koskenvuo M., et al. Environmental and heritable factors in the causation of cancer-analyses of cohort of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.; Sultanbaev A., Nasretdinov A., Sultanbaeva N., Minniakhmetov I., Menshikov K., Musin S. 12P EGFR gene mutations landscape at lung cancer in a multinational region located in the southeast of the European part of Russia. Ann Oncol. 2020;31(Suppl. 5):S1220–1. DOI:10.1016/j.annonc.2020.08.2171; Sultanbaev A., Nasretdinov A., Menshikov K., Sultanbaeva N., Musin Sh. Spectrum of mutations of epidermal growth factor genes in patients with lung cancer in the Republic of Bashkortostan. In: 46th Annual Meeting of Korean Cancer Association & 6th International Cancer Conference. Seoul, 2020. P. 188.; Hemminki K., Dong C., Vaittinen P. Cancer risks to spouses and offspring in the family-cancer database. Genet Epidemiol. 2001;20(2): 247–57. DOI:10.1002/1098-2272(200102)20:23.0.CO;2-U; Yamamoto H., Higasa K., Sakaguchi M., Shien K., Soh J., Ichimura K., et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Can Inst. 2014;106(1):djt3382014. DOI:10.1093/jnci/djt338; Bell D.W., Gore I., Okimoto R.A., GodinHeymann N., Sordella R., Mulloy R., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315–6. DOI:10.1038/ng1671; Oxnard G.R., Miller V.A., Robson M.E., Azzoli C.G., Pao W., Ladanyi M., et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012;7(6):1049–52. DOI:10.1097/JTO.0b013e318250ed9d; Имянитов Е.Н. Роль молекулярно-генетической диагностики в практической онкологии. Практическая онкология. 2019;20(4):261–73. DOI:10.31917/2004261; Султанбаев А.В, Насретдинов А.Ф., Гордиев М.Г., Пушкарев А.В., Мусин Ш.И., Султанбаева Н.И. и др. Персонифицированный подход в ранней диагностике и профилактике злокачественных новообразований. Тезисы. VI Петербургский международный онкологический форум «Белые ночи 2020». Санкт-Петербург, 2020. 111 с.; Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9. DOI:10.1158/1078-0432.CCR-10-2560; Насретдинов А.Ф., Султанбаева Н.И., Мусин Ш.И., Пушкарев А.В., Меньшиков К.В., Пушкарев В.А. и др. Уровень опухоль-инфильтрирующих лимфоцитов и PD- статус как возможные прогностические маркеры выживаемости и эффективности терапии при трижды негативном раке молочной железы. Опухоли женской репродуктивной системы. 2020;16(1):65–70. DOI:10.17650/1994-4098-2020-16-1-65-70; Prat J., Ribé A., Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861–70. DOI:10.1016/j.humpath.2005.06.006; Мусин Ш.И., Султанбаева Н.И., Насредтинов А.Ф., Пушкарев А.В., Пушкарев В.А., Меньшиков К.В. и др. Определение высокопенетрантных мутаций у больных раком молочной железы. Norwegian Journal of development of the International Science. 2020;(42-2):56–9.; Липатов О.Н., Султанбаева Н.И., Меньшиков К.В., Султанбаев А.В. Опыт определения мутаций в гене PIK3CA у больных раком молочной железы в Республике Башкортостан. Злокачественные oпухоли. 2020;10(3 Suppl. 1). DOI:10.18027/2224-5057; Antoniou A.C., Casadei S., Heikkinen T., Barrowdale D., Pylkäs K., Roberts J., et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. DOI:10.1056/NEJMoa1400382; Султанбаев А.В., Меньшиков К.В., Султанбаева Н.И., Мусин Ш.И., Минниахметов И.Р. Организация скрининга рака предстательной железы и носителей герминативных мутаций в генах BRCA1/2. Материалы XV международного конгресса Российского общества онкоурологов. М., 2020. С. 52.; Sultanbaev A., Nasretdinov A., Sultanbaeva N., Menshikov K., Musin S., Izmailov A., et al. Hereditary prostate cancer screening. Eur Urol Open Sci. 2020;21(Suppl 3):S155. DOI:10.1016/S2666-1683(20)36212-1; Sultanbaev A., Menshikov K., Sultanbaeva N., Nasretdinov A., Minniakhmetov I., Musin S., et al. Organization of screening for prostate cancer in carriers of germinal mutations in the BRCA1 / 2 genes. Eur Urol Open Sci. 2020;21(Suppl 3):S59. DOI:10.1016/S2666-1683(20)36064-X; Axilbund J.E., Wiley E.A. Genetic testing by cancer site: pancreas. Cancer J. 2012;18(4):350–4. DOI:10.1097/PPO.0b013e3182624694; Samadder N.J., Baffy N., Giridhar K.V., Couch F.J., Riegert-Johnson D. Hereditary cancer syndromes-a primer on diagnosis and management, Part 2: gastrointestinal cancer syndromes. Mayo Clin Proc. 2019;94(6):1099–116. DOI:10.1016/j.mayocp.2019.01.042; Carrera S., Sancho A., Azkona E., Azkuna J., Lopez- Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017;15:9. DOI:10.1186/s13053-017-0069-6; ten Broeke S.W., Brohet R.M., Tops C.M., van der Klift H.M., Velthuizen M.E., Bernstein I., et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2015;33(4):319–25. DOI:10.1200/JCO.2014.57.8088; Waller A., Findeis S., Lee M.J. Familial adenomatous polyposis. J Pediatr Genet. 2016;5(2):78–83. DOI:10.1055/s-0036-1579760; Talseth-Palmer B.A. The genetic basis of colonic adenomatous polyposis syndromes. Hered Cancer Clin Pract. 2017;15(1):5. DOI:10.1186/s13053-017-0065-x; Jelsig A.M., Qvist N., Brusgaard K., Nielsen C.B., Hansen T.P., Ousager L.B. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis. 2014;9:101. DOI:10.1186/1750-1172-9-101; Tavusbay C., Acar T., Kar H., Atahan K., Kamer E. The patients with Peutz-Jeghers syndrome have a high risk of developing cancer. Turk J Surg. 2018;34(2):162–4. DOI:10.5152/turkjsurg.2017.3241; Valdez J.M., Nichols K.E., Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 2017;176(4):539–52. DOI:10.1111/bjh.14461; Correa H. Li-Fraumeni Syndrome. J Pediatr Genet. 2016;5(2):84–8. DOI:10.1055/s-0036-1579759; McBride K.A., Ballinger M.L., Killick E., Kirk J., Tattersall M.H., Eeles R.A., et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260–71. DOI:10.1038/nrclinonc.2014.41; Bougeard G., Renaux-Petel M., Flaman J.M., Charbonnier C., Fermey P., Belotti M., et al. Revisiting Li- Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52. DOI:10.1200/JCO.2014.59.5728; Mai P.L., Best A.F., Peters J.A., DeCastro R.M., Khincha P.P., Loud J.T., et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–81. DOI:10.1002/cncr.30248; Fortuno C., James P., Spurdle A.B. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39(12):1764–73. DOI:10.1002/humu.23656; Zhang K., Zhou J., Zhu X., Luo M., Xu C., Yu J., et al. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Breast Cancer Res Treat. 2017;166(3):865–73. DOI:10.1007/s10549-017-4425-z; Norton J.A., Krampitz G., Jensen R.T. Multiple endocrine neoplasia: genetics and clinical management. Surg Oncol Clin N Am. 2015; 24(4): 795–832. DOI:10.1016/j.soc.2015.06.008; Goudet P., Dalac A., Le Bras M., Cardot-Bauters C., Niccoli P., Lévy-Bohbot N., et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568–77. DOI:10.1210/jc.2014-3659; Norton J.A., Kinz P.L. Multiple endocrine neoplasias. In: DeVita V.T., Lawrence T.S., Rosenberg S.A. (editors). Cancer: Principles and Practice of Oncology. LWW; 2015. P. 1227–34.; Eng C. Multiple endocrine neoplasia type 2. 1999 Sep 27 [updated 2019 Aug 15]. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., et al. (editors). GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–2020. PMID: 20301434; Tomuschat C., Puri P. RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis. Pediatr Surg Int. 2015;31:701–10. DOI:10.1007/s00383-015-3731-y; Rajagopala S.V., Vashee S., Oldfield L.M., Suzuki Y., Venter J.C., Telenti A., et al. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–34. DOI:10.1158/1940-6207.CAPR-16-0249; Garrett W.S. Cancer and the microbiota. Science. 2015;348:80–6. DOI:10.1126/science.aaa4972; Zhang J., Walsh M.F., Wu G., Edmonson M.N., Gruber T.A., Easton J., et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46. DOI:10.1056/NEJMoa1508054; University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800–13. DOI:10.1182/blood-2016-05-670240; Poggi M., Canault M., Favier M., Turro E., Saultier P., Ghalloussi D., et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282–94. DOI:10.3324/haematol.2016.147694; Melazzini F., Palombo F., Balduini A., De Rocco D., Marconi C., Noris P., et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101(11):1333–42. DOI:10.3324/haematol.2016.147496; Hyde R.K., Liu P.P. Germline PAX5 mutations and B cell leukemia. Nat Genet. 2013;45(10):1104–5. DOI:10.1038/ng.2778; Swaminathan M., Bannon S.A., Routbort M., Naqvi K., Kadia T.M., Takahashi K., et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5(1):a003210. DOI:10.1101/mcs.a003210; https://www.surgonco.ru/jour/article/view/537

الاتاحة: https://www.surgonco.ru/jour/article/view/537
https://doi.org/10.24060/2076-3093-2020-10-4-330-338

المؤلفون: Sh. Gantsev Kh., O. Lipatov N., K. Menshikov V., D. Tursumetov S., Kh. Saydulaeva S., Ш. Ганцев Х., О. Липатов Н., К. Меньшиков В., Д. Турсуметов С., Х. Сайдулаева С.

المصدر: Creative surgery and oncology; Том 10, № 3 (2020); 183-189 ; Креативная хирургия и онкология; Том 10, № 3 (2020); 183-189 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: liver neoplasms, hepatocellular carcinoma, viral hepatitis, tyrosine kinase inhibitors, targeted therapy, metastases, Lenvatinib, Sorafenib, печени новообразования, гепатоцеллюлярная карцинома, вирусные гепатиты, ингибиторы тирозинкиназ, таргетная терапия, метастазы, ленватиниб, сорафениб

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/503/405; Ивашкин В.Т., Маев И.В., Каприн А.Д., Агапов М.Ю., Андреев Д.Н., Водолеев А.С. и др. Раннее выявление онкологических заболеваний органов пищеварения (Методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(5):53–74. DOI:10.22416/1382-4376-2019-29-5-53-74; World health organization. Cancer [Internet]. WHO, 2018. [cited 2020 Sept 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer; Каприн А.Д., Старинский В.В., Петрова Г. В. (ред.) Злокачественные образования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена; 2019. 250 с.; Липатов О.Н., Меньшиков К.В., Турсуметов Д.С., Ахметгареева К.Т. Иммунотерапия гепатоцеллюлярного рака в Республике Башкортостан. Медицинский вестник Башкортостана. 2019;14(6):26–30.; Ахметгареева К.Т., Липатов О.Н., Меньшиков К.В., Султанбаев А.В. Заболеваемость первичным раком печени в Республике Башкортостан. В кн.: Белые ночи 2020: матер. VI Петербургского междунар. онкологического форума. СПб; 2020. С. 22.; Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14. DOI:10.1016/S0140-6736(18)30010-2; International Classification of Diseases for Oncology (ICD-O). 3rd edition, 1st revision. WHO; 2013. 242 p.; Pazgan-Simon M., Simon K.A., Jarowicz E., Rotter K., Szymanek-Pasternak A., Zuwała-Jagiełło J. Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence. Clin Exp Hepatol. 2018;4(3):210–6. DOI:10.5114/ceh.2018.78127; Levrero M., Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–S101. DOI:10.1016/j.jhep.2016.02.021; Brito A.F., Abrantes A.M., Tralhão J.G., Botelho M.F. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev. 2016;10(2):302. DOI:10.4081/oncol.2016.302; Лазаревич Н.Л., Кривцова О.М., Сковородникова П.А. Молекулярно-генетические особенности клинического прогноза ГЦР. Злокачественные опухоли. 2016; (4, спец. вып. 1):40–5. DOI:10.18027/2224-5057-2016-4s1-40-45; Kieran M.W., Kalluri R., Cho Y.J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012;2(12):a006593. DOI:10.1101/cshperspect.a006593; Бредер В.В., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Ледин Е.С., Петкау В.В. Практические рекомендации по лекарственному лечению гепатоцеллюлярного рака. Злокачественные опухоли. 2019;9:(3, спец. вып. 2):420–38. DOI:10.18027/2224-5057-2019-9-3s2-420-438; Ishihara S., Onoda N., Noda S., Asano Y., Tauchi Y., Morisaki T., et al. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status. Int J Oncol. 2019;55(5):1069–76. DOI:10.3892/ijo.2019.4881; Llovet J.M., Ricci S., Mazzaferro V., Hilgard Ph., Gane E., Blanc J.-F., et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359:378–90. DOI:10.1056/NEJMoa0708857; Kudo M., Finn R.S., Qin S., Kwang-Hyub Han, Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet. 2018;391:1163–73. DOI:10.1016/S0140-6736(18)30207-1; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI:10.3322/caac.21492; https://www.surgonco.ru/jour/article/view/503

الاتاحة: https://www.surgonco.ru/jour/article/view/503
https://doi.org/10.24060/2076-3093-2020-10-3-183-189